Aviir company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aviir.com

Founded Year

2005

Stage

Series D - III | Alive

Total Raised

$65.19M

Last Raised

$10M | 9 yrs ago

About Aviir

Aviir discovers, develops and commercializes diagnostic laboratory tests employing the latest technologies with a focus on cardiovascular disease along with related metabolic disorders. Beyond these novel tests, an extensive menu of standard of care cardiovascular & metabolic tests are provided through the company's CLIA certified laboratory. Aviir's MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years.

Aviir Headquarter Location

9805 Research Drive

Irvine, California, 92618,

United States

650-543-8200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aviir

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aviir is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Aviir News

Aviir Hits Milestones With Cardiovascular Diagnostic, Sees $30M Convert to Equity

Jun 22, 2013

Timothy Hay, (c) 2013 Dow Jones & Company, Inc. (c) 2013 Dow Jones & Company, Inc. Cardiovascular diagnostic company Aviir Inc . has raised a first equity round after reaching milestones and opening up a laboratory in Southern California--a lab that is now seeing brisk business--the company said. Founded in 2005, the company raised several previous rounds, including bridge financings, that have now converted to equity, bringing its total Series B round to $30 million, Chief Executive Douglas Harrington said.... Document DJFVW00020130621e96lruov3

  • When was Aviir founded?

    Aviir was founded in 2005.

  • Where is Aviir's headquarters?

    Aviir's headquarters is located at 9805 Research Drive, Irvine.

  • What is Aviir's latest funding round?

    Aviir's latest funding round is Series D - III.

  • How much did Aviir raise?

    Aviir raised a total of $65.19M.

  • Who are the investors of Aviir?

    Investors of Aviir include Aberdare Ventures, Bay City Capital, New Leaf Venture Partners, Merck Global Health Innovation Fund, Partners & Partners and 4 more.

  • Who are Aviir's competitors?

    Competitors of Aviir include Linkage Biosciences, VitaPath Genetics, Navigenics, MicroPhage, Crescent Diagnostics and 9 more.

You May Also Like

G
Genera Biosystems

Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.

H
Helix Diagnostics

Helix Diagnostics LLC is pursuing development and commercialization of multiplexed DNA detection systems based on capillary electrophoresis.

M
MicroPhage

MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.

I
Integrative Diagnostics

Integrative Diagnostics is a early cancer detection company founded by Leroy Hood.

3
3PrimiR

3PrimiR is researching how mutations in micro RNA molecules can be used in cancer diagnostics.

C
Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.